EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Prolactin in Polycystic Ovary Syndrome: Metabolic Effects and Therapeutic Prospects

Lara Mastnak, Rok Herman iD, Simona Ferjan, Andrej Janež iD, Mojca Jensterle iD

Life · 26.10.2023 · 13 (11) · 2124

DOI: 10.3390/life13112124 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Life, online erschienen am 26.10.2023. Verfasst von Lara Mastnak und 4 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 119 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Slovenian Research Agency (ARRS).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Polycystic ovary syndrome (PCOS) is the most prevalent endocrine and metabolic disorder in premenopausal women, characterized by hyperandrogenism, ovulatory dysfunction, and polycystic ovaries. Patients frequently present comorbidities, including obesity, insulin resistance, and impaired glucose and lipid metabolism. The diverse clinical presentation may mimic various endocrine disorders, making the diagnosis challenging in some clinical circumstances. Prolactin (PRL) is a recommended biomarker in the initial diagnostic workup to rule out hyperprolactinemia (HPRL). The traditional role of PRL is linked to lactation and the reproductive system. Recent research highlights PRL’s emerging role in metabolic homeostasis. PRL influences metabolism directly by interacting with the pancreas, liver, hypothalamus, and adipose tissue. Its influence on an individual’s metabolism is intricately tied to its serum concentration. While deficient and very high levels of PRL can negatively affect metabolism, intermediate–normal to moderately high levels may promote metabolic health. In women with PCOS, PRL levels may be altered. Research results on different aspects of the relationship between PCOS and the impact of various levels of PRL on metabolic homeostasis are limited and inconsistent. In this narrative literature review, we comprehensively examined data on serum PRL levels in PCOS patients. We investigated the correlation between a favorable metabolic profile and serum PRL levels in this population. Furthermore, we explored the concept of beneficial PRL effects on metabolism and discussed the potential therapeutic application of dopamine agonists in PCOS treatment. Lastly, we emphasized several promising avenues for future research in this field.

Schlagwörter

Stichwörter der Autor:innen

cardiometabolic markersdopamine agonistmetabolic homeostasispolycystic ovary syndromeprolactin

Autor:innen und Institutionen

  • Faculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia.
  • Department of Endocrinology, Diabetes and Metabolic Diseases, University Medical Center Ljubljana, 1000 Ljubljana, Slovenia.
  • Department of Internal Medicine, Faculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia.

ORCID-Profile: Rok Herman, Andrej Janež, Mojca Jensterle

Förderung

  • Slovenian Research Agency (ARRS)

Zitieren

APA

Mastnak, L., Herman, R., Ferjan, S., Janež, A., & Jensterle, M. (2023). Prolactin in Polycystic Ovary Syndrome: Metabolic Effects and Therapeutic Prospects. Life, 13(11), 2124. https://doi.org/10.3390/life13112124

Vancouver

Mastnak L, Herman R, Ferjan S, Janež A, Jensterle M. Prolactin in Polycystic Ovary Syndrome: Metabolic Effects and Therapeutic Prospects. Life. 2023;13(11):2124. doi:10.3390/life13112124

BibTeX
@article{Mastnak2023,
  author = {Mastnak, Lara and Herman, Rok and Ferjan, Simona and Janež, Andrej and Jensterle, Mojca},
  title = {Prolactin in Polycystic Ovary Syndrome: Metabolic Effects and Therapeutic Prospects},
  journal = {Life},
  year = {2023},
  volume = {13},
  number = {11},
  pages = {2124},
  doi = {10.3390/life13112124}
}
Kostenlos starten →